Covaxin: Phase 3 Clinical Trial Shows 81% Efficacy
NEW DELHI, Mar 3: India-made COVID-19 vaccine Covaxin has demonstrated an interim clinical efficacy of 81% in its Phase 3 clinical trial, vaccine maker Bharat Biotech said. Covaxin has demonstrated high clinical efficacy trend against COVID-19 as well as significant immunogenicity against the rapidly emerging variants, CMD Krishna Ella said. A statement from Bharat Biotech, […]


